Class Action Lawsuit Filed Against Anavex Life Sciences Corp.
Pomerantz Law Firm has filed a class action lawsuit against Anavex Life Sciences Corp. (NASDAQ: AVXL), alleging securities fraud or other unlawful business practices involving the company and certain officers or directors. Investors who purchased shares during the specified Class Period are advised to contact Pomerantz by November 30, 2026, to seek appointment as Lead Plaintiff. The lawsuit follows two significant events that impacted Anavex's stock price: first, on May 6, 2026, when CEO Christopher Missling was terminated for cause, leading the company’s share price to drop by $0.22 (or 6.59%) in one day; and second, on August 28, 2026, after Anavex disclosed a material weakness in internal controls over financial reporting, causing another decline of $0.19 per share (6.35%). Pomerantz LLP is recognized for its expertise in securities class actions and has secured significant damages on behalf of investors in the past.
Tickers: $AVXL
Topics: CEO termination material weakness in internal controls securities fraud